DK0428038T3 - Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol - Google Patents

Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol

Info

Publication number
DK0428038T3
DK0428038T3 DK90121170.6T DK90121170T DK0428038T3 DK 0428038 T3 DK0428038 T3 DK 0428038T3 DK 90121170 T DK90121170 T DK 90121170T DK 0428038 T3 DK0428038 T3 DK 0428038T3
Authority
DK
Denmark
Prior art keywords
tetrahydrobenzothiazole
propylamino
amino
transdermal administration
transdermal
Prior art date
Application number
DK90121170.6T
Other languages
Danish (da)
English (en)
Inventor
Bernd Dr Zierenberg
Michael Dr Herschel
Uwe Dr Rohr
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK0428038T3 publication Critical patent/DK0428038T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK90121170.6T 1989-11-09 1990-11-06 Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol DK0428038T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3937271A DE3937271A1 (de) 1989-11-09 1989-11-09 Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol

Publications (1)

Publication Number Publication Date
DK0428038T3 true DK0428038T3 (da) 1994-08-29

Family

ID=6393163

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90121170.6T DK0428038T3 (da) 1989-11-09 1990-11-06 Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol

Country Status (17)

Country Link
US (1) US5112842A (cs)
EP (1) EP0428038B1 (cs)
JP (1) JP3034588B2 (cs)
KR (1) KR0184867B1 (cs)
AT (1) ATE108668T1 (cs)
AU (1) AU635358B2 (cs)
CA (1) CA2029524C (cs)
CZ (1) CZ277718B6 (cs)
DE (2) DE3937271A1 (cs)
DK (1) DK0428038T3 (cs)
ES (1) ES2058725T3 (cs)
FI (1) FI905531A7 (cs)
HU (1) HU206043B (cs)
IE (1) IE65564B1 (cs)
IL (1) IL96276A (cs)
NZ (1) NZ236002A (cs)
ZA (1) ZA908953B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400649A1 (de) * 1984-01-11 1985-07-18 Jonny 4000 Düsseldorf Janus Fahrzeugrad
DE69333009T2 (de) * 1992-11-09 2003-12-04 Neurogesx, Inc. Transdermale verabreichung von ketorolac
US6486310B1 (en) * 1993-01-28 2002-11-26 Washington University Gene encoding the rat dopamine D4 receptor
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
JP2009102351A (ja) * 1997-07-17 2009-05-14 Nitto Denko Corp 貼付剤
AU760439B2 (en) * 1998-05-15 2003-05-15 Pharmacia & Upjohn Company Cabergoline and pramipexole: new uses and combinations
EA200300125A1 (ru) * 1998-05-15 2003-06-26 Фармация Энд Апджон Компани Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича
EP1591119A3 (en) * 1998-05-15 2007-03-28 Pharmacia & Upjohn Company LLC Pramipexole for treating CNS diseases, especially Parkinson's disease
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US20080262053A1 (en) * 2005-10-18 2008-10-23 Juergen Reess Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
ITMI20060044A1 (it) * 2006-01-13 2007-07-14 Dipharma Spa Sintesi di intermedi pr la preparazione di pramipexolo
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
WO2008001200A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
KR101307334B1 (ko) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012205493A1 (de) 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
JPWO2015129527A1 (ja) * 2014-02-27 2017-03-30 株式会社 メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
CN109310526B (zh) * 2016-10-07 2022-05-17 全崴生技股份有限公司 普拉克索经皮贴片系统与用法
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
WO2019049145A1 (en) 2017-09-11 2019-03-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
US4826686A (en) * 1985-12-14 1989-05-02 Boehringer Ingelheim Kg Therapeutic system
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents

Also Published As

Publication number Publication date
ATE108668T1 (de) 1994-08-15
CZ277718B6 (en) 1993-03-17
JPH03170425A (ja) 1991-07-24
EP0428038A2 (de) 1991-05-22
DE59006506D1 (de) 1994-08-25
US5112842A (en) 1992-05-12
IL96276A0 (en) 1991-08-16
HU907065D0 (en) 1991-05-28
ES2058725T3 (es) 1994-11-01
EP0428038B1 (de) 1994-07-20
IE904021A1 (en) 1991-05-22
CA2029524A1 (en) 1991-05-10
ZA908953B (en) 1992-07-29
IE65564B1 (en) 1995-11-01
HU206043B (en) 1992-08-28
FI905531A0 (fi) 1990-11-08
CS553490A3 (en) 1992-04-15
EP0428038A3 (en) 1991-09-25
JP3034588B2 (ja) 2000-04-17
IL96276A (en) 1994-11-28
KR910009264A (ko) 1991-06-28
AU6650890A (en) 1991-05-16
AU635358B2 (en) 1993-03-18
KR0184867B1 (ko) 1999-05-01
HUT59005A (en) 1992-04-28
NZ236002A (en) 1993-01-27
DE3937271A1 (de) 1991-05-16
CA2029524C (en) 2002-12-31
FI905531A7 (fi) 1991-05-10

Similar Documents

Publication Publication Date Title
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
IT9047580A0 (it) Procedimento di trattamento di polveri inorganiche.
PT921812E (pt) Preparacoes de insulina contendo um halogenuro
IT8720200A0 (it) Agenti stabilizzanti costituiti da 1,3,2-ossazafosfolidine.
IT1212088B (it) Derivati piperazinici ad attivita'anticolinergica e/o antiistaminica.
NO903527D0 (no) Laboratorieanordning, samt fremgangsmaate for behandling av steinproever.
DE69002520D1 (de) Azeotropaehnliche zusammensetzungen von 1,1-dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1-fluoraethan.
NO860733L (no) N-(2-klor-4-trifluormethylfenyl)-3-trifluormethyl-benzensulfonamidderivat, fremgangsmaate for fremstilling av dette, og fungicid middel inneholdende dette.
DK627289D0 (da) Anvendelse af bicyclononanderivater
PT99061A (pt) Combinacoes de substancias activas do tipo piretroide, contendo benflutrin e pralletrin
IT8821300A0 (it) Procedimento di preparazione di morniflumato e analoghi.
FI844645L (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
NO904016L (no) Paafoerings-hjelpemiddel samt anvendelse av dette.
NO903347D0 (no) Fremgangsmaate for fremstilling av 14,17alfa-ethano- og ethanooestratriener.
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
FI874450A7 (fi) Farmaseuttiset valmisteet alkuperältään toiminnallisten ja elimelliste n aivohäiriöiden hoitamiseen.
DK632388A (da) Pharmaceutisk middel til behandling af hyperlipidaemi hol pattedyr
DE3770301D1 (de) N2-(1-carboxy-3-oxo-3-phenylpropyl)-l-lysinverbindungen und deren abkoemmlinge.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DE3670085D1 (de) 2-(1-hydroxy-2,2,6,6-tetraalkyl-piperidin-4-yloxy)-dibenzodioxaphosphepine und dibenzodioxaphosphocine.
DK160821C (da) 1,3-dihydro-4-benzoyl-2h-imidazol-2-oner samt middel til behandling af hjertesvigt
FI872363A7 (fi) Bakteriosiinit ja niitä sisältävät koostumukset virusinfektioiden detektioon ja hoitoon.
NO883987D0 (no) Fremgangsmaate for fremstilling av n-(substituert aklyliden) kondensert bicykloalkyliden og anvendelse derav som medikamenter.
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.